lassa fever DNA vaccine

A Lassa fever DNA vaccine is a prophylactic immunization strategy that utilizes DNA plasmid technology to induce protective immune responses against the Lassa virus (LASV). These vaccines typically consist of engineered plasmids encoding specific viral antigens, most commonly the Lassa virus glycoprotein precursor (GPC) and occasionally the nucleoprotein (NP). Upon administration—often via electroporation to enhance cellular uptake—host cells take up the DNA and express the encoded antigens, which are then presented to the immune system to stimulate both humoral (antibody) and cellular (T-cell) immunity. This platform is particularly valued for its stability, ease of rapid manufacture, and ability to drive robust CD8+ T-cell responses, which are critical for controlling viral infections. The most prominent candidate in this category is Inovio Pharmaceuticals' INO-4500, which has been evaluated in clinical trials supported by the Coalition for Epidemic Preparedness Innovations (CEPI).

Other names

lassa fever deoxyribonucleic acid vaccineLASV DNA vaccine